高级检索
当前位置: 首页 > 详情页

Preoperative prediction of IDH genotypes and prognosis in adult-type diffuse gliomas: intratumor heterogeneity habitat analysis using dynamic contrast-enhanced MRI and diffusion-weighted imaging

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Radiol, Shanghai 200127, Peoples R China [2]Shanghai Jiao Tong Univ, Sch Med, Tongren Hosp, Dept Radiol, Shanghai 200336, Peoples R China [3]Siemens Healthineers Ltd, MR Res Collaborat Team, Shanghai 200126, Peoples R China [4]Fudan Univ, Huashan Hosp, Dept Radiol, Shanghai 200040, Peoples R China [5]Shanghai Jiao Tong Univ, Sch Med, Coll Hlth Sci & Technol, Shanghai 200025, Peoples R China
出处:
ISSN:

关键词: Adult-type diffuse glioma Intratumor heterogeneity Isocitrate dehydrogenase Progression-free survival Dynamic contrast-enhanced perfusion Diffusion-weighted imaging

摘要:
Background Intratumor heterogeneity (ITH) is a key biological characteristic of gliomas. This study aimed to characterize ITH in adult-type diffuse gliomas and assess the feasibility of using habitat imaging based on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) to preoperatively predict isocitrate dehydrogenase (IDH) genotypes and prognosis. Methods Sixty-three adult-type diffuse gliomas with known IDH genotypes were enrolled. Volume transfer constant (K-trans) and apparent diffusion coefficient (ADC) maps were acquired from DCE-MRI and DWI, respectively. After tumor segmentation, the k-means algorithm clustered K-trans and ADC image voxels to generate spatial habitats and extract quantitative image features. Receiver operating characteristic (ROC) curves and area under the curve (AUC) were used to evaluate IDH predictive performance. Multivariable logistic regression models were constructed and validated using leave-one-out cross-validation, and the contrast-enhanced subgroup was analyzed independently. Kaplan-Meier and Cox proportional hazards regression analyses were used to investigate the relationship between tumor habitats and progression-free survival (PFS) in the two IDH groups. Results Three habitats were identified: Habitat 1 (hypo-vasopermeability and hyper-cellularity), Habitat 2 (hypo-vasopermeability and hypo-cellularity), and Habitat 3 (hyper-vasopermeability). Compared to the IDH wild-type group, the IDH mutant group exhibited lower mean K-trans values in Habitats 1 and 2 (both P < 0.001), higher volume (P < 0.05) and volume percentage (pVol, P < 0.01) of Habitat 2, and lower volume and pVol of Habitat 3 (both P < 0.001). The optimal logistic regression model for IDH prediction yielded an AUC of 0.940 (95% confidence interval [CI]: 0.880-1.000), which improved to 0.948 (95% CI: 0.890-1.000) after cross-validation. Habitat 2 contributed the most to the model, consistent with the findings in the contrast-enhanced subgroup. In IDH wild-type group, pVol of Habitat 2 was identified as a significant risk factor for PFS (high- vs. low-pVol subgroup, hazard ratio = 2.204, 95% CI: 1.061-4.580, P = 0.034), with a value below 0.26 indicating a 5-month median survival benefit. Conclusions Habitat imaging employing DCE-MRI and DWI may facilitate the characterization of ITH in adult-type diffuse gliomas and serve as a valuable adjunct in the preoperative prediction of IDH genotypes and prognosis. Clinical trial number Not applicable.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2024]版:
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 肿瘤学 2 区 核医学
JCR分区:
出版当年[2023]版:
Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Q2 ONCOLOGY
最新[2023]版:
Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者:
第一作者机构: [1]Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Radiol, Shanghai 200127, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Radiol, Shanghai 200127, Peoples R China [5]Shanghai Jiao Tong Univ, Sch Med, Coll Hlth Sci & Technol, Shanghai 200025, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:22952 今日访问量:1 总访问量:1267 更新日期:2025-03-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)